Summit Therapeutics (SMMT) Capital Expenditures (2017 - 2026)
Summit Therapeutics' (SMMT) quarterly Capital Expenditures came in at $217000.0 in Q2 2026, down 90.37% YoY from $2.3 million in Q2 2025, and down 78.85% on a QoQ basis from $1.0 million in Q1 2026.
Summit Therapeutics (SMMT) Capital Expenditures (2017 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 10 years of Capital Expenditures data on file, last reported at $217000.0 in Q2 2026.
- Quarterly Capital Expenditures fell 90.37% year-over-year to $217000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.8 million (down 128.34% YoY) and the FY2025 annual result came in at $657000.0, up 372.66% from the prior year.
- Capital Expenditures fell to $217000.0 in Q2 2026, from $1.0 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $2.6 million in Q4 2024 to a low of -$3.9 million in Q4 2025.
- A 5-year average of $155055.6 and a median of $53000.0 in 2023 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 129650.0% in 2024, down 4715.09% in 2024.
- Tracing SMMT's Capital Expenditures over 5 years: stood at -$10000.0 in 2022, then jumped by 120.0% to $2000.0 in 2023, then surged by 129650.0% to $2.6 million in 2024, then tumbled by 249.17% to -$3.9 million in 2025, then soared by 105.61% to $217000.0 in 2026.
- The last three Capital Expenditures figures came in at $217000.0 (Q2 2026), $1.0 million (Q1 2026), and -$3.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 217,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 217,000.00 |
| Jun 30, 2026 | 217,000.00 |
| Mar 31, 2026 | 1.03 Mn |
| Mar 31, 2026 | 1.03 Mn |
| Dec 31, 2025 | -3.87 Mn |
| Dec 31, 2025 | -3.87 Mn |
| Sep 30, 2025 | 856,000.00 |
| Sep 30, 2025 | 856,000.00 |
| Jun 30, 2025 | 2.25 Mn |
| Jun 30, 2025 | 2.25 Mn |
| Mar 31, 2025 | 1.42 Mn |
| Mar 31, 2025 | 1.42 Mn |
| Dec 31, 2024 | 2.60 Mn |
| Dec 31, 2024 | 2.60 Mn |
| Sep 30, 2024 | -14,000.00 |
| Sep 30, 2024 | -14,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | -2.45 Mn |
| Mar 31, 2024 | -2.45 Mn |